Resmed Inc (RMD): Michael J. Farrell , Chief Executive Officer of Resmed Inc sold 5,975 shares on Apr 15, 2016. The Insider selling transaction was reported by the company on Apr 19, 2016 to the Securities and Exchange Commission. The shares were sold at $59.34 per share for a total value of $354,556.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 12, 2016, Peter C Farrell (director) sold 20,000 shares at $58.62 per share price.On Apr 5, 2016, David Pendarvis (Chief Administrative Officer) sold 6,000 shares at $58.70 per share price.Also, On Mar 17, 2016, Michael J. Farrell (Chief Executive Officer) sold 5,975 shares at $58.57 per share price.On Mar 16, 2016, James Hollingshead (President, Americas) sold 4,500 shares at $58.57 per share price.
ResMed: On Monday, Apr 18, 2016 heightened volatility was witnessed in ResMed which led to swings in the share price. The shares opened for trading at $59.45 and hit $60.21 on the upside , eventually ending the session at $59.9, with a gain of 0.25% or 0.15 points. The heightened volatility saw the trading volume jump to 5,19,468 shares. The 52-week high of the share price is $74.14 and the company has a market cap of $8,388 M . The 52-week low of the share price is at $48.99.
Company has been under the radar of several Street Analysts.ResMed is Resumed by Barclays to Underweight and the brokerage firm has set the Price Target at $55. The Rating was issued on Apr 7, 2016.ResMed is Upgraded by Credit Suisse to Outperform. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Jan 22, 2016.
Currently the company Insiders own 2.54% of ResMed shares according to the proxy statements.In the past twelve weeks, the net percent change held by company insiders has changed by -13.03%.Institutional Investors own 58.45% of ResMed shares.During last six month period, the net percent change held by insiders has seen a change of -19.03%.
ResMed Inc. is engaged in the development manufacturing distribution and marketing of medical products for the diagnosis treatment and management of respiratory disorders with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders including airflow generators diagnostic products mask systems headgear and other accessories. It produces continuous positive airway pressure variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape AirSense 10 Elite AirSense 10 CPAP S9 VPAP S S9 VPAP ST S9 VPAP Adapt S9 VPAP ST-A S9 VPAP COPD and AirCurve 10 V Auto among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX Swift FX for Her Mirage FX for Her Pixi Pediatric Mask Quattro FX for Her Swift FX Bella Swift FX Nano AirFit N10 and Apnealink Air.